What are alternative medications to bosentan (an endothelin‑receptor antagonist) for pulmonary arterial hypertension when bosentan is unavailable?

Alternative Endothelin Receptor Antagonists to Bosentan

If bosentan is unavailable for pulmonary arterial hypertension, use ambrisentan (5-10 mg daily) or macitentan (10 mg daily) as alternative endothelin receptor antagonists, both of which are equally effective and have more favorable hepatotoxicity profiles. 1

First-Line Alternatives Within the Same Drug Class

The most straightforward substitution when bosentan is unavailable is to use another endothelin receptor antagonist (ERA), as three oral ERAs are approved for PAH treatment:

Ambrisentan

• Dosing: Start at 5 mg daily, increase to 10 mg daily if tolerated and treatment goals not met 1
• Advantages: Once-daily dosing improves compliance; lower incidence of hepatotoxicity (2.8% at 1 year) compared to bosentan (10%) 2, 3
• Evidence: Improves 6-minute walk distance (6MWD), WHO functional class, and delays time to clinical worsening in WHO FC II-III patients 4, 2
• Monitoring: Monthly liver function tests no longer mandated by FDA due to rarity of transaminase elevations, though many clinicians continue monitoring 5

Macitentan

• Dosing: 10 mg once daily 1
• Advantages: Demonstrated reduction in morbidity/mortality events; improved WHO functional class and delays clinical worsening 4, 6
• Evidence: Recent prospective data shows patients switched from bosentan to macitentan due to inadequate response had significant improvements: 22% moved to lower risk stratification, mean 6MWD increased 34 meters at 12 months, with excellent safety profile (no anemia or liver injury) 7

Important caveat: All ERAs are teratogenic and contraindicated in pregnancy. Monthly pregnancy testing required in women of childbearing potential. Barrier contraception mandatory as hormonal contraceptives may be less effective with ERAs 2.

Alternative Drug Classes When ERAs Are Not Options

If all ERAs are unavailable or contraindicated, consider these alternative pathways:

Phosphodiesterase-5 Inhibitors (PDE5i)

• Sildenafil: 20 mg three times daily (FDA-approved dose); can titrate to 80 mg TID if inadequate response 4
• Tadalafil: 40 mg once daily 1
• Evidence: Both improve 6MWD, WHO functional class, and hemodynamics in WHO FC II-III patients 4
• Advantage: Different mechanism (enhances NO-cGMP pathway) with distinct side effect profile

Soluble Guanylate Cyclase Stimulator

• Riociguat: 0.5-1 mg three times daily, titrated by 0.5 mg every 2 weeks to maximum 2.5 mg TID 1
• Evidence: Improves 6MWD, WHO FC, delays clinical worsening, and improves hemodynamics 4
• Critical warning: Contraindicated with PDE5i due to systemic hypotension risk 4

Prostacyclin Pathway Agents

For more severe disease (WHO FC III-IV) or inadequate response to oral agents:

• Inhaled iloprost: 2.5-5 μg per dose, 6-9 times daily 1
• Subcutaneous/IV treprostinil: Continuous infusion starting 0.625-1.25 ng/kg/min 1
• IV epoprostenol: 1-12 ng/kg/min continuous infusion; only therapy proven to improve survival in randomized trials for IPAH 8, 3

Combination Therapy Considerations

Recent high-quality evidence strongly supports initial combination therapy over sequential monotherapy. The 2019 AMBITION trial demonstrated that upfront combination of ambrisentan plus tadalafil reduced clinical failure events by 50% compared to monotherapy 6, 9. This represents a paradigm shift from stepwise escalation to preemptive combination therapy.

Recommended Combinations:

• Ambrisentan + Tadalafil: Grade 1B evidence for WHO FC II-III 6, 9
• Any ERA + PDE5i: Grade IIa-C for WHO FC II-III 6
• ERA or PDE5i + prostacyclin analogue: Grade IIa-C for WHO FC III-IV 6

Clinical Decision Algorithm

For WHO FC II-III patients previously on bosentan:

1. First choice: Switch to ambrisentan or macitentan (same drug class, proven efficacy)
2. If ERA unavailable/contraindicated: Use PDE5i (sildenafil or tadalafil)
3. If inadequate response to monotherapy: Add second agent from different class (preferably ERA + PDE5i combination)
4. If WHO FC III with rapid progression or WHO FC IV: Consider adding prostacyclin pathway agent or switching to IV epoprostenol

For systemic sclerosis-associated PAH: Note that response to pharmacologic intervention is generally less impressive than in idiopathic PAH 4. Consider more aggressive combination therapy earlier.

Critical Monitoring Requirements

All ERAs require:

• Monthly liver function tests (bosentan and macitentan; ambrisentan less stringent but recommended)
• Monthly pregnancy tests in women of childbearing potential
• Hemoglobin monitoring every 3 months (risk of anemia)
• Counseling regarding potential male infertility/testicular atrophy 2

The evidence strongly supports that switching between ERAs is both safe and effective when clinical response is inadequate 7, 10, making ambrisentan or macitentan excellent alternatives when bosentan is unavailable.